Abstract:
Objective:
To evaluate the efficacy and tolerability of ranolazine as an addon
drug in chronic stable angina patients and
the impact of ranolazine on the quality of life in chronic stable angina patients receiving other antianginal
medications.
Materials and Methods:
It was a prospective, openlabel,
hospitalbased
study involving 144 patients with chronic stable angina. First
group received either metoprolol 12.5 or 25 mg/day or other antianginal medications; if the symptoms persist,
the dose of metoprolol was increased to 50 mg/day, and to the second group, ranolazine 500 mg BD or 1 g
OD was added along with metoprolol or others if the anginal attacks were not subsiding. The patients were
followed up to 6 months with electrocardiography, treadmill test, and quality of life questionnaire. Adverse
events were recorded at each visit during the study.
Results:
There was a statistically significant reduction in weekly anginal frequency (P < 0.001) and improvement in
an exercise tolerance in both the groups, but more in the ranolazine group. Adverse events reported were
mild, infrequent.
Conclusion:
Ranolazine is could be used as an addon
drug in chronic angina patients not improved with metoprolol or
antianginal medications.
